Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients
Adding peg-interferon to standard treatment helps some hepatitis B patients
This meta-analysis of 581 patients with chronic hepatitis B evaluates peg-interferon add-on to nucleoside analogue therapy. The analysis fou…
Adding peg-interferon to standard nucleoside therapy can help some patients with chronic hepatitis B achieve a key milestone in their treatm…
Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B
Immune Markers May Predict Outcomes After Hepatitis B Treatment
This mini review synthesizes immune correlates of outcome after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Bene…
New research identifies specific immune markers that may help predict how patients respond when stopping nucleoside analogue medications for…
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B
Combination therapies may improve functional cure rates for chronic hepatitis B
This narrative review examines combining pegylated interferon-α with novel immunotherapies (antigen-reduction strategies, therapeutic vaccin…
A review suggests combining pegylated interferon with new immunotherapies could help achieve functional cure in chronic hepatitis B patients…
Phase 2 trial of JNJ-73763989-based regimen shows no HBsAg seroclearance at primary endpoint in HBeAg-positive CHB
New combo lowers hepatitis B virus levels
A phase 2 trial in 54 treatment-naïve, HBeAg-positive chronic hepatitis B patients tested a regimen of JNJ-73763989 ± bersacapavir with nucl…
A new drug combination successfully lowered virus levels in many patients, though clearing the virus completely happened in only about one o…